Case reports in pediatrics · 2026
Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brown Georgia, McNab Sarah, Keogh Susan, Massie John, Eastaugh Lucas, Pathmanathan Lydia, Bertinetti Monique, Sullivan Michael, Orme Lisa, Cloney Thomas, Brown Natasha J, Tan Tiong Y, Quin Rebecca, Pertile Mark, Moon Anna, Bekhit Elhamy, Penington Tony
Аннотация
INTRODUCTION: Kaposiform lymphangiomatosis (KLA) is a rare and aggressive lymphatic anomaly characterised by chylous effusions, respiratory failure and poor prognosis. Diagnosis is often challenging and delayed due to the mosaic distribution of causative somatic mutations.
CASE PRESENTATION: A previously well four-year-old girl presented with pleural and pericardial effusions and methicillin-sensitive Staphylococcus aureus bacteraemia. She was treated with intravenous antibiotics, and chest and pericardial drains were inserted. Despite these measures, she developed high-volume, refractory chylous effusions. Management included dietary modification, as well as trials of octreotide and intravenous methylprednisolone, neither of which reduced chyle output. Magnetic resonance lymphangiography demonstrated diffuse abdominal and thoracic lymphatic abnormalities. She was subsequently treated with sirolimus, which was associated with reduced pleural and pericardial chylous drainage but ongoing clinical deterioration. Cell-free DNA analysis of pleural fluid identified a somatic NRAS variant (NM_002524.5 (NRAS):c.182A > G (p.Gln61Arg)). In the absence of histopathology, a presumed diagnosis of NRAS Q61R-driven KLA was made based on clinical, radiologic and molecular findings. She was started on trametinib, a MEK inhibitor. Over the subsequent 7 weeks, she was weaned from respiratory support and parenteral nutrition, transitioned to a fat-containing diet and experienced resolution of clinically significant effusions, allowing discharge home.
CONCLUSION: This case highlights the diagnostic challenges of complex lymphatic anomalies, demonstrates the utility of cell-free DNA analysis from effusions in identifying pathogenic somatic variants and underscores the therapeutic potential of targeted MEK inhibition in NRAS Q61R-driven KLA.
CASE PRESENTATION: A previously well four-year-old girl presented with pleural and pericardial effusions and methicillin-sensitive Staphylococcus aureus bacteraemia. She was treated with intravenous antibiotics, and chest and pericardial drains were inserted. Despite these measures, she developed high-volume, refractory chylous effusions. Management included dietary modification, as well as trials of octreotide and intravenous methylprednisolone, neither of which reduced chyle output. Magnetic resonance lymphangiography demonstrated diffuse abdominal and thoracic lymphatic abnormalities. She was subsequently treated with sirolimus, which was associated with reduced pleural and pericardial chylous drainage but ongoing clinical deterioration. Cell-free DNA analysis of pleural fluid identified a somatic NRAS variant (NM_002524.5 (NRAS):c.182A > G (p.Gln61Arg)). In the absence of histopathology, a presumed diagnosis of NRAS Q61R-driven KLA was made based on clinical, radiologic and molecular findings. She was started on trametinib, a MEK inhibitor. Over the subsequent 7 weeks, she was weaned from respiratory support and parenteral nutrition, transitioned to a fat-containing diet and experienced resolution of clinically significant effusions, allowing discharge home.
CONCLUSION: This case highlights the diagnostic challenges of complex lymphatic anomalies, demonstrates the utility of cell-free DNA analysis from effusions in identifying pathogenic somatic variants and underscores the therapeutic potential of targeted MEK inhibition in NRAS Q61R-driven KLA.